KR20140025470A - 트리아졸로피리딘 - Google Patents
트리아졸로피리딘 Download PDFInfo
- Publication number
- KR20140025470A KR20140025470A KR1020137030546A KR20137030546A KR20140025470A KR 20140025470 A KR20140025470 A KR 20140025470A KR 1020137030546 A KR1020137030546 A KR 1020137030546A KR 20137030546 A KR20137030546 A KR 20137030546A KR 20140025470 A KR20140025470 A KR 20140025470A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- phenyl
- triazolo
- pyridin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC(CC1)=CC(CC2C=C3C=CC(c4ccc(C)cc4)=CC3*2)=C1OC Chemical compound CC(CC1)=CC(CC2C=C3C=CC(c4ccc(C)cc4)=CC3*2)=C1OC 0.000 description 3
- FYNHIXKZJPVUPL-UHFFFAOYSA-N CC(C)(CO)NC(c(cc1)cc(OC)c1Br)=O Chemical compound CC(C)(CO)NC(c(cc1)cc(OC)c1Br)=O FYNHIXKZJPVUPL-UHFFFAOYSA-N 0.000 description 1
- GKBPNRRBFVBNJE-UHFFFAOYSA-N CC(N(C)CCN(C)C(c(cc1)cc(OC)c1Br)=O)=O Chemical compound CC(N(C)CCN(C)C(c(cc1)cc(OC)c1Br)=O)=O GKBPNRRBFVBNJE-UHFFFAOYSA-N 0.000 description 1
- BUKGAGAOTDVLSS-UHFFFAOYSA-N CCN(C=C)C(C(C=CC1(C)Br)=CC1OCC)=O Chemical compound CCN(C=C)C(C(C=CC1(C)Br)=CC1OCC)=O BUKGAGAOTDVLSS-UHFFFAOYSA-N 0.000 description 1
- CECJCVOLFDPIIF-UHFFFAOYSA-N CCN(CC)C(c(cc1)cc(OCC2CC2)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1)=O Chemical compound CCN(CC)C(c(cc1)cc(OCC2CC2)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1)=O CECJCVOLFDPIIF-UHFFFAOYSA-N 0.000 description 1
- ZJGUHNGHOAHSBU-UHFFFAOYSA-N CCNC(C(C=CC1(C)Nc2n[n](cc(cc3)-c(cc4)ccc4C(NCC4CC4)=O)c3n2)=CC1OCC(F)(F)F)=O Chemical compound CCNC(C(C=CC1(C)Nc2n[n](cc(cc3)-c(cc4)ccc4C(NCC4CC4)=O)c3n2)=CC1OCC(F)(F)F)=O ZJGUHNGHOAHSBU-UHFFFAOYSA-N 0.000 description 1
- AIZQPQWHUCVGAO-UHFFFAOYSA-N CCOCCNC(c(cc1)cc(OC)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)=O Chemical compound CCOCCNC(c(cc1)cc(OC)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)=O AIZQPQWHUCVGAO-UHFFFAOYSA-N 0.000 description 1
- OOLTUNIXMHQJGE-UHFFFAOYSA-N CCOc(cc(cc1)C(NC(C)(C)CO)=O)c1Br Chemical compound CCOc(cc(cc1)C(NC(C)(C)CO)=O)c1Br OOLTUNIXMHQJGE-UHFFFAOYSA-N 0.000 description 1
- GSYULZYCZBRKGK-UHFFFAOYSA-N CCOc(cc(cc1)C(NCCS(C)(=O)=O)=O)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1 Chemical compound CCOc(cc(cc1)C(NCCS(C)(=O)=O)=O)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1 GSYULZYCZBRKGK-UHFFFAOYSA-N 0.000 description 1
- PDCHGIILPOFEHU-UHFFFAOYSA-O CCOc(cc(cc1)[N+](O)=O)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCC3CC3)=O)c2n1 Chemical compound CCOc(cc(cc1)[N+](O)=O)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCC3CC3)=O)c2n1 PDCHGIILPOFEHU-UHFFFAOYSA-O 0.000 description 1
- QBFWKHWSZDXECM-UHFFFAOYSA-N CCOc1cc(S(CC)(=O)=O)ccc1Br Chemical compound CCOc1cc(S(CC)(=O)=O)ccc1Br QBFWKHWSZDXECM-UHFFFAOYSA-N 0.000 description 1
- SXMSMZWRXJKOOS-UHFFFAOYSA-N CCOc1cc(S(CC)(=O)=O)ccc1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1 Chemical compound CCOc1cc(S(CC)(=O)=O)ccc1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1 SXMSMZWRXJKOOS-UHFFFAOYSA-N 0.000 description 1
- WAPGIGHNANPHAZ-UHFFFAOYSA-N CNC(c(cc1)cc(OC)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)=O Chemical compound CNC(c(cc1)cc(OC)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)=O WAPGIGHNANPHAZ-UHFFFAOYSA-N 0.000 description 1
- CRTOFESISWFZAU-UHFFFAOYSA-N COc(cc(CO)cc1)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1 Chemical compound COc(cc(CO)cc1)c1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1 CRTOFESISWFZAU-UHFFFAOYSA-N 0.000 description 1
- DMAJORPFXLBYCW-UHFFFAOYSA-N COc(cc(cc1)C#N)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1 Chemical compound COc(cc(cc1)C#N)c1Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3F)=O)c2n1 DMAJORPFXLBYCW-UHFFFAOYSA-N 0.000 description 1
- MMBNWTKRVCOPSO-UHFFFAOYSA-N CS(c(cc1OCC(F)(F)F)ccc1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)(=O)=O Chemical compound CS(c(cc1OCC(F)(F)F)ccc1Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc(cc3)ccc3F)=O)c2n1)(=O)=O MMBNWTKRVCOPSO-UHFFFAOYSA-N 0.000 description 1
- BNLMHIWPPSPPIQ-UHFFFAOYSA-N CSc(cc1)cc(OC2CC2)c1Br Chemical compound CSc(cc1)cc(OC2CC2)c1Br BNLMHIWPPSPPIQ-UHFFFAOYSA-N 0.000 description 1
- FCLQGYJCCHLWMU-UHFFFAOYSA-N Cc(cc(cc1)-c2c[n]3nc(Nc(ccc(S(C)(=O)=O)c4)c4OCC(F)(F)F)nc3cc2)c1C(NCc(cc1)ccc1F)=O Chemical compound Cc(cc(cc1)-c2c[n]3nc(Nc(ccc(S(C)(=O)=O)c4)c4OCC(F)(F)F)nc3cc2)c1C(NCc(cc1)ccc1F)=O FCLQGYJCCHLWMU-UHFFFAOYSA-N 0.000 description 1
- BZXMUSAMMGLTMI-UHFFFAOYSA-N FC(Oc(cc(cc1)F)c1Br)F Chemical compound FC(Oc(cc(cc1)F)c1Br)F BZXMUSAMMGLTMI-UHFFFAOYSA-N 0.000 description 1
- YTAYAIVHNAZCJQ-UHFFFAOYSA-N NC(c(cc1)cc(OC(F)(F)F)c1Br)=O Chemical compound NC(c(cc1)cc(OC(F)(F)F)c1Br)=O YTAYAIVHNAZCJQ-UHFFFAOYSA-N 0.000 description 1
- KCPCWQTXCQHDQK-UHFFFAOYSA-N Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc3cccc(F)c3)=O)c2n1 Chemical compound Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc3cccc(F)c3)=O)c2n1 KCPCWQTXCQHDQK-UHFFFAOYSA-N 0.000 description 1
- MDIUAJGCUCHRHJ-UHFFFAOYSA-N Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc3ccccc3)=O)c2n1 Chemical compound Nc1n[n](cc(cc2)-c(cc3)ccc3C(NCc3ccccc3)=O)c2n1 MDIUAJGCUCHRHJ-UHFFFAOYSA-N 0.000 description 1
- CFAZMKSFISYJMD-UHFFFAOYSA-N Nc1n[n](cc(cc2)-c(cc3)ccc3NC(CC3CC3)=O)c2n1 Chemical compound Nc1n[n](cc(cc2)-c(cc3)ccc3NC(CC3CC3)=O)c2n1 CFAZMKSFISYJMD-UHFFFAOYSA-N 0.000 description 1
- WHXOQMCREVXCDV-UHFFFAOYSA-N Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3Cl)=O)c2n1 Chemical compound Nc1n[n](cc(cc2)-c(cc3)ccc3NC(Cc(cc3)ccc3Cl)=O)c2n1 WHXOQMCREVXCDV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163342.6 | 2011-04-21 | ||
| EP11163342 | 2011-04-21 | ||
| EP11167872.8 | 2011-05-27 | ||
| EP11167872 | 2011-05-27 | ||
| PCT/EP2012/056914 WO2012143329A1 (en) | 2011-04-21 | 2012-04-16 | Triazolopyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140025470A true KR20140025470A (ko) | 2014-03-04 |
Family
ID=46124297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137030546A Ceased KR20140025470A (ko) | 2011-04-21 | 2012-04-16 | 트리아졸로피리딘 |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013027096A2 (pt) | 2011-04-21 | 2016-12-27 | Gilead Sciences Inc | compostos de benzotiazol e seu uso farmacêutico |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| CA2878481A1 (en) | 2012-07-10 | 2014-01-16 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014195274A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| JP2016527193A (ja) * | 2013-06-07 | 2016-09-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジン |
| SG11201509351UA (en) * | 2013-06-10 | 2015-12-30 | Bayer Pharma AG | Novel compounds for the treatment of cancer |
| HK1219879A1 (zh) * | 2013-06-11 | 2017-04-21 | Bayer Pharma Aktiengesellschaft | 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 |
| RS56034B1 (sr) * | 2013-06-11 | 2017-09-29 | Bayer Pharma AG | Derivati prolekova supstituisanih triazolopiridina |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| FI3283642T3 (fi) | 2015-04-17 | 2024-01-11 | Crossfire Oncology Holding B V | Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan |
| CN109963854B (zh) * | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| NZ780966A (en) | 2019-04-18 | 2026-02-27 | Univ Johns Hopkins | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| MX2007001943A (es) | 2004-08-17 | 2007-05-09 | Galderma Res & Dev | Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas. |
| JP5336375B2 (ja) * | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| US8053574B2 (en) | 2007-07-18 | 2011-11-08 | Novartis Ag | Organic compounds |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| CA2691448A1 (en) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX2010005700A (es) * | 2007-11-27 | 2010-06-11 | Cellzome Ltd | Amino triazoles como inhibidores pi3k. |
| SG173610A1 (en) | 2009-02-13 | 2011-09-29 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| CN102413831B (zh) | 2009-04-29 | 2014-06-04 | 拜耳知识产权有限责任公司 | 取代的咪唑并喹喔啉 |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2012
- 2012-04-16 HR HRP20150517TT patent/HRP20150517T1/hr unknown
- 2012-04-16 EP EP12721779.2A patent/EP2699575B1/en active Active
- 2012-04-16 PL PL12721779T patent/PL2699575T3/pl unknown
- 2012-04-16 CA CA2833657A patent/CA2833657A1/en not_active Abandoned
- 2012-04-16 DK DK12721779.2T patent/DK2699575T3/da active
- 2012-04-16 ME MEP-2015-80A patent/ME02143B/me unknown
- 2012-04-16 MY MYPI2013701964A patent/MY164939A/en unknown
- 2012-04-16 KR KR1020137030546A patent/KR20140025470A/ko not_active Ceased
- 2012-04-16 ES ES12721779.2T patent/ES2539265T3/es active Active
- 2012-04-16 SI SI201230220T patent/SI2699575T1/sl unknown
- 2012-04-16 AP AP2013007182A patent/AP3491A/xx active
- 2012-04-16 CN CN201280030682.XA patent/CN103608350B/zh not_active Expired - Fee Related
- 2012-04-16 JP JP2014505584A patent/JP5989091B2/ja not_active Expired - Fee Related
- 2012-04-16 HU HUE12721779A patent/HUE025496T2/en unknown
- 2012-04-16 PT PT127217792T patent/PT2699575E/pt unknown
- 2012-04-16 SG SG2013073044A patent/SG194003A1/en unknown
- 2012-04-16 AU AU2012244859A patent/AU2012244859B2/en not_active Ceased
- 2012-04-16 MX MX2013012289A patent/MX348783B/es active IP Right Grant
- 2012-04-16 PH PH1/2013/502169A patent/PH12013502169A1/en unknown
- 2012-04-16 PE PE2013002378A patent/PE20141351A1/es not_active Application Discontinuation
- 2012-04-16 US US14/113,017 patent/US20140120087A1/en not_active Abandoned
- 2012-04-16 RS RS20150345A patent/RS54044B1/sr unknown
- 2012-04-16 WO PCT/EP2012/056914 patent/WO2012143329A1/en not_active Ceased
- 2012-04-16 EA EA201301181A patent/EA023766B1/ru not_active IP Right Cessation
- 2012-04-16 MA MA36344A patent/MA35049B1/fr unknown
- 2012-04-18 JO JOP/2012/0093A patent/JO3040B1/ar active
- 2012-04-18 SA SA112330466A patent/SA112330466B1/ar unknown
- 2012-04-20 UY UY0001034034A patent/UY34034A/es not_active Application Discontinuation
- 2012-04-20 TW TW101114259A patent/TWI558703B/zh not_active IP Right Cessation
- 2012-04-20 AR ARP120101355A patent/AR086191A1/es unknown
-
2013
- 2013-10-03 IL IL228704A patent/IL228704A0/en unknown
- 2013-10-18 GT GT201300254A patent/GT201300254A/es unknown
- 2013-10-21 CO CO13248763A patent/CO6801751A2/es active IP Right Grant
- 2013-10-21 DO DO2013000244A patent/DOP2013000244A/es unknown
- 2013-10-21 CL CL2013003044A patent/CL2013003044A1/es unknown
- 2013-10-21 CR CR20130539A patent/CR20130539A/es unknown
- 2013-11-05 EC ECSP13013011 patent/ECSP13013011A/es unknown
- 2013-11-20 ZA ZA2013/08707A patent/ZA201308707B/en unknown
-
2015
- 2015-06-12 CY CY20151100512T patent/CY1116439T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5805654B2 (ja) | トリアゾロピリジン誘導体 | |
| EP2507235B1 (en) | Triazolopyrimidines | |
| JP5989091B2 (ja) | トリアゾロピリジン類 | |
| EP2507233B1 (en) | Substituted triazolopyridines | |
| JP5951750B2 (ja) | 置換イミダゾピリジン類およびその中間体 | |
| KR20130116067A (ko) | 치환된 트리아졸로피리딘 | |
| HK1190398B (en) | Triazolopyridines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20131118 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170412 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180601 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20181001 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20180601 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |